Physician profile

Andrew V Cichelli

Pulmonary Disease · Statesboro, GA

NPI 1710044557

$11,698.62

in general payments reported to CMS, 2019-2025

46 companies · $2,623 in 2025

The $2,623 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,140.10
Education$252.05
Consulting Fee$200.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $1,576.88 2019-2025 Trelegy Ellipta, Nucala, Arexvy
Actelion Pharmaceuticals US, INC. $1,314.79 2019-2025 Opsumit, Uptravi, Opsynvi
Astrazeneca Pharmaceuticals LP $1,111.35 2019-2025 Fasenra, Airsupra, Tezspire
Jazz Pharmaceuticals INC. $676.02 2019-2025 Xywav
Insmed, INC. $629.63 2019-2025 Arikayce, Brinsupri
Boehringer Ingelheim Pharmaceuticals, INC. $602.93 2019-2025 Ofev, Jascayd, Stiolto Respimat
Harmony Biosciences LLC $597.03 2020-2024 Wakix
Bayer Healthcare Pharmaceuticals INC. $588.61 2019-2025
Mylan Specialty L.P. $543.25 2019-2024 Yupelri
Regeneron Healthcare Solutions, INC. $522.40 2019-2025 Dupixent
Grifols USA, LLC $379.93 2020-2025 Prolastin-C Liquid
United Therapeutics Corporation $348.71 2019-2024 Orenitram, Remodulin
Takeda Pharmaceuticals U.S.A., INC. $318.65 2020-2025 Glassia
Axsome Therapeutics, INC. $293.11 2022-2025 Sunosi
Genzyme Corporation $226.89 2024-2025
Show all 46 companies
CompanyGeneral paymentsYearsTop products
Mallinckrodt Hospital Products INC. $205.12 2020-2023 Acthar
Merck Sharp & Dohme LLC $201.62 2024-2025 Winrevair, Capvaxive, Gardasil 9
Verona Pharma, INC. $157.88 2025 Ohtuvayre
Janssen Pharmaceuticals, INC $153.98 2019-2021
Ani Pharmaceuticals, INC. $138.85 2024-2025 Purified Cortrophin Gel
Avadel Cns Pharmaceuticals, LLC $100.83 2023-2025 Lumryz
Amgen INC. $92.53 2022-2025 Tezspire
Stryker Corporation $77.89 2025 Ct Thrombectomy System Kit, Flowtriever Catheter, S, Flowtriever
Baxter Healthcare $64.29 2022-2025 Hillrom - Vest System Model 105 Home Care
Advanced Respiratory, INC $58.56 2019-2021
Olympus America INC. $58.01 2021-2022
Sanofi-Aventis U.S. LLC $54.95 2025
Abbvie INC. $51.37 2022
Genentech USA, INC. $51.11 2019
Viatris Specialty LLC $50.92 2025 Yupelri
Idorsia Pharmaceuticals US INC $43.97 2023 Quviviq
Pfizer INC. $42.10 2021-2025
3b Medical, INC. $41.37 2025 Luna
Medtronic, INC. $38.54 2021
Vifor Pharma, INC. $35.92 2024-2025 Zemaira
Veran Medical Technologies, INC. $32.32 2020-2021
Johnson & Johnson Health Care Systems INC. $30.75 2023 Opsumit
Allergan, INC. $24.91 2019-2020
Mallinckrodt Enterprises LLC $24.81 2019
Shionogi INC $23.88 2023 Fetroja
Cvrx, INC. $21.01 2025 Barostim Neo System
La Jolla Pharmaceutical Company $20.42 2022
Electromed, INC. $20.33 2025 Smartvest
Lilly USA, LLC $19.00 2025 Zepbound
Philips North America LLC $17.39 2022
Arbor Pharmaceuticals, INC. $13.81 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Andrew V Cichelli

$11,698.62

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $2,623 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/258723/andrew-v-cichelli

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.